{
    "ucits": true,
    "type": "ETP",
    "leverage": true,
    "derivatives": true,
    "swaps": false,
    "inverse": false,
    "replication_method": "synthetic",
    "complex_factors": "Leverage, Synthetic replication, Derivative use, Compounding effect, Structured product features",
    "classification": "complex",
    "supporting_data": "The product is a Leverage Shares 5x Long Magnificent 7 ETP Securities, which is a collateralised exchange traded security (ETP), not a UCITS ETF. It provides 5 times the daily performance of the Solactive Magnificent 7 Index, implying significant leverage (5x). The product uses derivatives as an inherent part of its investment strategy to achieve leveraged exposure, not merely for efficient portfolio management. The replication method is synthetic, relying on derivatives rather than physical holdings. The product documentation explicitly warns about the compounding effect, daily rebalancing, and the high risk (risk class 7/7). It is intended for sophisticated investors with the ability to monitor frequently and understand complex risks such as leverage and compounding. The product is not capital protected and involves counterparty and collateral risks inherent in derivative usage. According to MiFID II Article 25(4)(a)(vi) and Article 57 of the Delegated Regulation, such leveraged, synthetic, derivative-based products with complex payoff structures are classified as complex. The product also carries a mandatory comprehension alert in its KID, confirming its complex status. Although it is UCITS compliant (as per the issuer's regulatory status), the product's structure and features place it outside the typical non-complex UCITS ETF category. Therefore, it must be classified as complex under MiFID II appropriateness rules."
}